GlaxoSmithKline Pharmaceuticals Limited announces results for the quarter ended December 31, 2020
EBITDA Margin @ 24%; Sales +10%
GlaxoSmithKline Pharmaceuticals Limited today declared its f inancial results for the quarter ended 31 st December 2020. Revenue for the quarter came in at Rs. 858 crores clocking a growth of 10% as compared to the quarter ended 31st December 2019. Profit After Tax came in at Rs 157 crores.
Commenting on the results, Sridhar Venkatesh, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said,
“GSK demonstrated a strong rebound with sales growing by ~33% from Q1FY21 post a decline in the pandemic peak, as most of our key brands gained market share and outpaced their competitor brands. Vaccines and respiratory remain important growth areas for us and expected to grow in higher double digits.
GSK will continue to focus on its innovation and our product pipeline as we build on the momentum generated by the recently launched Fluarix Tetra, Menveo, and Nucala.”
About GlaxoSmithKline Pharmaceuticals Limited
GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GlaxoSmithKline plc, one of the world's leading research-based pharmaceutical and healthcare companies, committed to improving the quality of human lif e by enabling people to do more, feel better and live longer. For more information, visit www.gsk-india.com
Media Contact:
Ransom D’Souza Vice President
Corporate Communications and Government Affairs
GlaxoSmithKline Pharmaceuticals Limited
Email: ransom.a.dsouza@gsk.com
Tel: +91 22 24959203
